Weston Nichols
@Lynx1 Capital Management Lp
Latest period2024 - Q3ReportedManaged Assets$282.238MTotal holdings18
Assets growth rate1.82%Assets growth rate (2-Q avg)-13.39%Continuous growth in asset value1 quarters
Portfolio positions
This chart displays the top 10 holdings in Lynx1 Capital Management Lp's 2024 - Q3 portfolio, based on their 13F SEC filing, out of a total of 18 positions.
Assets under management
The assets under management (AUM) of Lynx1 Capital Management Lp over the past 10 years (40 quarters) show continuous growth in total asset value over the last 1 quarters. As of the latest 13F SEC filing for 2024 - Q3, they manage 282.238M in assets, with a quarterly growth rate of 1.82% and a 2-quarter average growth rate of -13.39%. The portfolio is managed by Weston Nichols, and others.
Portfolio holdings
Investment | Portfolio % | Reported Value | Recent Activity |
---|---|---|---|
MRUSMerus N V
| 31.76% | $89.622M 1.794M shares@ $49.96 avg price | Increased 48.66% |
STOKStoke Therapeutics Inc
| 22.59% | $63.751M 5.187M shares@ $12.29 avg price | Increased 0.04% |
CCCCC4 Therapeutics Inc
| 13.9% | $39.219M 6.881M shares@ $5.71 avg price | |
GHRSGh Research Plc
| 9.95% | $28.071M 4.196M shares@ $6.7 avg price | Increased 5.78% |
TCRXTscan Therapeutics Inc
| 9.22% | $26.019M 5.225M shares@ $4.98 avg price | |
ALLOAllogene Therapeutics Inc
| 6.16% | $17.367M 6.202M shares@ $2.8 avg price | Increased 178.35% |
CGEMCullinan Therapeutics Inc
| 2.44% | $6.877M 410,830 shares@ $16.74 avg price | Increased 8.89% |
PASGPassage Bio Inc
| 2.1% | $5.899M 8.427M shares@ $0.71 avg price | Increased 66.62% |
IBIOIbio Inc
| 0.68% | $1.914M 862,279 shares@ $2.22 avg price | Increased 2.56% |
CRBUCaribou Biosciences Inc
| 0.48% | $1.333M 680,189 shares@ $1.96 avg price | New Position |